Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 1
2013 6
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Legendre CM, et al. N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981. N Engl J Med. 2013. PMID: 23738544 Free article. Clinical Trial.
BACKGROUND: Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. ...METHODS: We conducted two prospective phase 2 trials in which patients with atypical hemolyti
BACKGROUND: Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-med …
Eculizumab in atypical hemolytic-uremic syndrome.
Tanimoto T, Oshima Y, Kami M. Tanimoto T, et al. N Engl J Med. 2013 Oct 3;369(14):1378-9. doi: 10.1056/NEJMc1308826. N Engl J Med. 2013. PMID: 24088109 No abstract available.
Eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM, Licht C, Loirat C. Legendre CM, et al. N Engl J Med. 2013 Oct 3;369(14):1379-80. doi: 10.1056/NEJMc1308826. N Engl J Med. 2013. PMID: 24088105 No abstract available.
Eculizumab in atypical hemolytic-uremic syndrome.
Amadio A, Tejani AM. Amadio A, et al. N Engl J Med. 2013 Oct 3;369(14):1378. doi: 10.1056/NEJMc1308826. N Engl J Med. 2013. PMID: 24088107 No abstract available.
Eculizumab in atypical hemolytic-uremic syndrome.
Kistler AD. Kistler AD. N Engl J Med. 2013 Oct 3;369(14):1378. doi: 10.1056/NEJMc1308826. N Engl J Med. 2013. PMID: 24088108 Free article. No abstract available.
More on eculizumab for congenital atypical hemolytic-uremic syndrome.
Shin JI, Lee JS. Shin JI, et al. N Engl J Med. 2009 May 14;360(20):2142-3; author reply 2143. doi: 10.1056/NEJMc090453. N Engl J Med. 2009. PMID: 19439754 No abstract available.
Eculizumab for atypical hemolytic-uremic syndrome.
Nürnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M. Nürnberger J, et al. N Engl J Med. 2009 Jan 29;360(5):542-4. doi: 10.1056/NEJMc0808527. N Engl J Med. 2009. PMID: 19179328 No abstract available.
Eculizumab for congenital atypical hemolytic-uremic syndrome.
Gruppo RA, Rother RP. Gruppo RA, et al. N Engl J Med. 2009 Jan 29;360(5):544-6. doi: 10.1056/NEJMc0809959. N Engl J Med. 2009. PMID: 19179329 No abstract available.
Eculizumab in atypical hemolytic-uremic syndrome.
Ring T. Ring T. N Engl J Med. 2013 Oct 3;369(14):1377-8. doi: 10.1056/NEJMc1308826. N Engl J Med. 2013. PMID: 24088106 No abstract available.
Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.
Zimmerhackl LB, Hofer J, Cortina G, Mark W, Würzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W. Zimmerhackl LB, et al. N Engl J Med. 2010 May 6;362(18):1746-8. doi: 10.1056/NEJMc1001060. N Engl J Med. 2010. PMID: 20445192 No abstract available.
Feedback